Drug Profile


Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 02 Oct 2017 Janssen Research and Development files sNDA to reduce the risk of major adverse cardiovascular events composed of cardiovascular death, myocardial infarction and stroke patients with Type 2 diabetes mellitus in USA
  • 01 Oct 2017 Johnson & Johnson files a MAA to reduce the risk of death or risk for cardiovascular events in patients with Type 2 diabetes mellitus in USA (Johnson & Johnson pipeline, October 2017)
  • 11 Sep 2017 Long term safety and efficacy data from a phase IV trial in Type 2 diabetes presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top